https://mirror.vjregenmed.com The Video Journal of Regenerative Medicine Wed, 25 Aug 2021 11:22:49 +0000 en-US hourly 1 https://wordpress.org/?v=6.5.2 https://d2xz56kaqxj8if.cloudfront.net/wp-content/uploads/2023/09/12102509/VJR-Favicon.png https://mirror.vjregenmed.com 32 32 https://mirror.vjregenmed.com/video/rg90oiouawo-a-look-into-the-future-car-t-and-bispecifics-in-myeloma/ Fri, 26 Feb 2021 14:08:23 +0000 http://13.40.107.223/video/rg90oiouawo-a-look-into-the-future-car-t-and-bispecifics-in-myeloma/ Maria-Victoria Mateos, MD, PhD, University of Salamanca, Salamanca, Spain, discusses the future of CAR T-cell therapy and bispecific monoclonal antibodies in multiple myeloma. When approved, the optimal use for these therapies would be in triple-refractory myeloma patients, but these strategies will move into earlier lines of treatment in the future. Currently, ongoing clinical trials are evaluating the role of bispecifics and CAR T-cells following one/three prior lines of therapy. While other trials are evaluating the safety and efficacy of CAR T-cells in the front-line setting in patients with high-risk myeloma. Dr Mateos highlights different strategies, currently being investigated in preliminary clinical trials, to improve the efficacy of BCMA CAR T-cells. In the bispecific antibody field, new targets beyond BCMA are being investigated, including GPRC5D-directed bispecifics, as well as novel combinations of immune and targeted therapies. This interview took place during the 3rd European CAR T-cell Meeting.

]]>